Recurrent Clostridium Difficile vs Post Infectious IBS: A Prospective Study


About this study

The purpose of this study is to assess patients suspected of recurrent C. difficile disease (rCDI) and using a combination of clinical and laboratory markers to determine disease versus post infectious irritable bowel syndrome (IBS) with C. difficile colonization.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Adults >18years of age
  2. Attending Mayo Clinic
  3. At least 1 prior documented episode of CDI
  4. Presenting with diarrhea with at least 3 bowel movements/24 hours of Bristol type 6-7, no alternative diagnosis
  5. Not started on antimicrobial treatment
  6. Written informed consent


Exclusion Criteria: 

  1. Prior diagnosis of Irritable Bowel Syndrome
  2. Fulminant CDI (hypotension or shock, ileus, or megacolon)
  3. Severe CDI (WBC >15,000/ul , or creatinine >1.5 mg/dL)
  4. Diagnosed Inflammatory Bowel Disease
  5. Concomitant laxative intake

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sahil Khanna, M.B.B.S.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Renee Weatherly

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available